Danielle M Brander MD

PubMed

• Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era.
  Cecelia R Miller, Ying Huang, John N Allan, Seema A Bhat, David Bond
  American Journal of Hematology. 2025-09-01
• Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Ly...
  Mohamed A Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, Jennifer R Brown, Mazyar Shadman
  Transplantation and Cellular Therapy. 2025-08-01
• 12 citations
  Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQ...
  Mazyar Shadman, Talha Munir, Tadeusz Robak, Jennifer R Brown, Brad S Kahl
  Journal of Clinical Oncology. 2025-03-01

Journal Articles

• SET Alpha and SET Beta mRNA Isoforms in Chronic Lymphocytic Leukaemia  
  Danielle M Brander, J Brice Weinberg, Daphne R Friedman, Thomas J Kipps, British Journal of Haematology

Abstracts/Posters

• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Danielle M. Brander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
  Danielle M. Brander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  Danielle M. Brander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
  Danielle M. Brander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents
  Danielle M. Brander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Danielle M. Brander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
  Danielle M. Brander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
  Danielle M. Brander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Indefinite Oral Therapy for Frontline Chronic Lymphocytic Leukemia Treatment: Give Me All You’ve... 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
• Expert Perspectives on the Role of BTK Inhibitors in CLL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients ... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all